Johnson & Johnson
(BSP:JNJB34)
R$
60.12
0 (0%)
Market Cap: 2.18 Til
Enterprise Value: 2.27 Til
PE Ratio: 24.52
PB Ratio: 5.08
GF Score: 76/100 Johnson & Johnson at Wells Fargo Healthcare Conference Transcript
Sep 07, 2023 / 02:15PM GMT
Release Date Price:
R$52.59
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
All right. Good morning. I'm Larry Biegelsen, the medical device analyst at Wells Fargo, and it's my pleasure to host this session with the management team from J&J. With us, we have Ashley McEvoy, Executive Vice President and Worldwide Chairman of Medical Devices, as well as several members from the Abiomed team: Michael Bodner, Global Head of Heart Recovery; Andrew Greenfield, Worldwide President; and Chuck Simonton, Chief Medical Officer and Global VP of Clinical and Medical Affairs.
We're going to start with Abiomed because Ashley is running a few minutes late, but I've been told she will be here momentarily. So gentlemen, thanks so much for being here.
Michael Bodner
Abiomed, Inc. - Global Leader Heart Recovery
Thank you for having us.
Questions & Answers
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot